CRISTINA M. FISCHER,ERIC A SCHMITT,HUAILIANG WU,JONATHAN MARK MILLER,JUSTIN S. LAFOUNTAINE,KATHERINE HEEMSTRA,PING TONG,YANXIA LI
申请号：
BRPI1012959
公开号：
BRPI1012959A2
申请日:
2010.06.08
申请国别(地区):
BR
年份:
2016
代理人:
摘要：
A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound, e.g., ABT-263, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.
